Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug
|
Lenacapavir is already approved for treatment of HIV,
and is under regulatory review for prevention, but it has a price tag of
$42,250. As a result, ... |
Impact of US funding cuts on HIV programmes in Angola
While stocks of antiretroviral supplies, HIV, viral load and other lab test kits are available, recent reports indicate challenges with distribution. View article...